Our results with transplanted TSC2−/− AML organoids in RNU rats prompted us to use this animal model to examine the effect of a nanoparticle formulation for delivery of the mTOR inhibitor rapamycin, a compound used for the treatment of AML tumors in TSC patients33. Here, MTOR is linked to tuberous sclerosis.